Bellicum Pharmaceuticals Inc. [NASDAQ: BLCM] traded at a high on 04/27/23, posting a 23.51 gain after which it closed the day’ session at $0.41. The company report on March 14, 2023 at 4:30 PM that Bellicum Discontinues Phase 1/2 Trials and Initiates Evaluation of Strategic Alternatives.
The most recent patient treated in the Phase 1/2 trial of BPX-601 in metastatic castration-resistant prostate cancer (mCRPC) experienced serious immune-mediated adverse events including Grade 4 cytokine release syndrome (CRS), the second dose-limiting toxicity observed in this cohort of dose escalation. The company paused enrollment in its clinical studies and conducted a thorough review of the risk/benefit observed to date. While clinically meaningful efficacy has been observed—including 5 of 9 mCRPC patients treated achieving PSA50 response, 4 of whom achieved PSA90 response—the Company believes it does not have the necessary resources to optimize either the clinical dose and schedule of BPX-601 cells and the activating agent rimiducid, or the design of the BPX-601 cell construct to achieve a favorable risk/benefit profile.
Unlock the Hottest Top 10 Penny Stocks Today! Discover Now
Dive into the world of lucrative penny stocks with MarketClub's groundbreaking "Smart Scan" technology! Get an instant snapshot of the top 50 high volume stocks with a clear direction and outstanding liquidity - in other words, the strongest trending. To unlock this exclusive list, simply provide your first name, last name, and email for instant access.
Gain Access to Top 10 Penny Stocks Now!.
The results of the trading session contributed to over 4597923 shares changing hands. Over the past one week, the price volatility of Bellicum Pharmaceuticals Inc. stands at 25.49% while the volatility over the past one month is 31.82%.
The market cap for BLCM stock reached $4.30 million, with 30.83 million shares outstanding and 8.50 million shares in the current float. Compared to the average trading volume of 1.03M shares, BLCM reached a trading volume of 4597923 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Bellicum Pharmaceuticals Inc. [BLCM]?
Wells Fargo have made an estimate for Bellicum Pharmaceuticals Inc. shares, keeping their opinion on the stock as Equal Weight, with their previous recommendation back on October 30, 2020. The new note on the price target was released on October 30, 2020, representing the official price target for Bellicum Pharmaceuticals Inc. stock. On April 12, 2018, analysts increased their price target for BLCM shares from 10 to 18.
The Average True Range (ATR) for Bellicum Pharmaceuticals Inc. is set at 0.11, with the Price to Sales ratio for BLCM stock in the period of the last 12 months amounting to 2.87. The Price to Book ratio for the last quarter was 5.93, with the Price to Cash per share for the same quarter was set at 2.10.
How has BLCM stock performed recently?
Bellicum Pharmaceuticals Inc. [BLCM] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 6.68. With this latest performance, BLCM shares gained by 59.62% in over the last four-week period, additionally sinking by -60.29% over the last 6 months – not to mention a drop of -75.59% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for BLCM stock in for the last two-week period is set at 49.77, with the RSI for the last a single of trading hit 55.93, and the three-weeks RSI is set at 45.73 for Bellicum Pharmaceuticals Inc. [BLCM]. The present Moving Average for the last 50 days of trading for this stock 0.5742, while it was recorded at 0.3524 for the last single week of trading, and 0.9948 for the last 200 days.
Bellicum Pharmaceuticals Inc. [BLCM]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Bellicum Pharmaceuticals Inc. [BLCM] shares currently have an operating margin of -1798.73 and a Gross Margin at +99.27. Bellicum Pharmaceuticals Inc.’s Net Margin is presently recorded at -1664.87.
Return on Equity for this stock declined to -79.94, with Return on Assets sitting at -68.45.
Bellicum Pharmaceuticals Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 6.30 and a Current Ratio set at 6.30.
Insider trade positions for Bellicum Pharmaceuticals Inc. [BLCM]
There are presently around $1 million, or 31.40% of BLCM stock, in the hands of institutional investors. The top three institutional holders of BLCM stocks are: IKARIAN CAPITAL, LLC with ownership of 448,101, which is approximately 0% of the company’s market cap and around 3.80% of the total institutional ownership; LONG FOCUS CAPITAL MANAGEMENT, LLC, holding 327,692 shares of the stock with an approximate value of $0.11 million in BLCM stocks shares; and BAKER BROS. ADVISORS LP, currently with $84000.0 in BLCM stock with ownership of nearly 0% of the company’s market capitalization.
Positions in Bellicum Pharmaceuticals Inc. stocks held by institutional investors increased at the end of Thursday and at the time of the Thursday reporting period, where 11 institutional holders increased their position in Bellicum Pharmaceuticals Inc. [NASDAQ:BLCM] by around 115,711 shares. Additionally, 7 investors decreased positions by around 196,400 shares, while 17 investors held positions by with 1,382,882 shares. The mentioned changes placed institutional holdings at 1,694,993 shares, according to the latest SEC report filing. BLCM stock had 7 new institutional investments in for a total of 96,267 shares, while 2 institutional investors sold positions of 13,066 shares during the same period.